Discovery NM/CT 670 CZT
Molecular imaging enables the search for a different kind of discovery. The kind that has the ability to have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.
The search for true discovery is unique. It requires the right balance of technology and people. The technology to enable the search and the people to embrace it. People open to opportunity, who persistently look for a better way to do something. To continuously improve the world around them. The kind of person that embodies the spirit of discovery.
We collaborate every day with the great minds working in molecular imaging. It is through these partnerships that we recognize your ambition. We see your attempts to diagnose and stage disease earlier to improve patient outcomes. We know firsthand of your desire to conduct exciting research such as simultaneous dual-isotope studies so you can expand the reach of nuclear medicine's impact. And we realize you are continually trying to provide the most comfortable experience possible for your patients.
We share in your drive to make things better. It's why, for the past 60 years, we have stayed committed to developing the potential of nuclear medicine. And, it's what led us to the breakthrough CZT technology. Not every technological innovation has the ability to transform how we see and understand the world around us. CZT does. Its revolutionary detection capability is not only transforming our understanding of disease at the cellular level, it's even being used to record events at the astronomical level.
Introducing DiscoveryTM NM/CT 670 CZT, the first commercially-available general purpose SPECT/CT system powered by CZT technology. Help bring your theories to life with a system designed to leverage all that CZT can do. Engineered for improvements in lesion detection1, image quality and patient comfort and combined with advanced quantitative applications provided through XelerisTM, this system renews the promise of nuclear medicine's potential for true discovery.
THE MOLECULAR IMAGING AND COMPUTED TOMOGRAPHY MAGAZINE
Clarity is back. We intend to publish Clarity semi-annually to offer you the latest information on both Molecular Imaging and CT innovations at GE Healthcare, all designed to help you achieve the best possible outcomes.
Click here to sign up for your complimentary subscription so you don’t miss a single edition of Clarity.